FOSTER CITY, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in the following upcoming investor conferences in March.

TD Cowen 44^th Annual Health Care Conference
Date/Time: Monday, March 4, 2024 at 12:50 p.m. ET
Format: Panel Presentation
Location: Boston, MA

Inaugural BMO Obesity Summit
Date/Time: Wednesday, March 20, 2024 at 11:00 a.m. ET
Format: Company Presentation
Location: New York, NY

Live webcasts of the events will be available on the investor relations page of Terns’ website at http://ir.ternspharma.com. A replay of the webcasts will be archived on Terns’ website for at least 30 days following the presentations.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline includes three clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, and a THR-β agonist, and a preclinical GIPR modulator program. For more information, please visit: www.ternspharma.com.

Contacts for Terns

Investors
Justin Ng
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media
Jenna Urban
Berry & Company Public Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.